Tesaro 3000-01-004- An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study To Assess The Relative Bioavailability And Bioequivalence Of Niraparib Tablet Formulation Compared To Niraparib Capsule Formulation In Patients With Advanced Solid
Posted Date: Jul 1, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to obtain preliminary assessment of the relative bioavailability (BA) of 300mg niraparib administered as a tablet versus capsule formulation and to estimate the intrasubject variability of niraparib PK
Criteria:
To Be Eligible: Age 18 Or Older, Nonpregnant/Breastfeeding, No P-Glycoprotein Inhibitors, No Gastric Or Esophageal Cancer
Keywords:
Cancer, Tumor, Advanced
For More Information:
Uccc Cancer Center
513-584-7698
cancer@uchealth.com